Oddo BHF raised target for Novo Nordisk stock from DKK 221 to DKK 305
Published on 10/26/2026 at 16:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Oddo BHF raised its Novo Nordisk target from DKK 221 to DKK 305 on October 20, 2026.
- Novo Nordisk had repurchased 39.07 million B shares for DKK 10.88 billion by October 16, 2026.
- Novo Nordisk stock costs EUR 34.88 at Lang & Schwarz on October 26, 2026 at 4:14 p.m. CEST, 0.34 percent below the Xetra close of October 23, 2026, and 34.75 percent below the 52-week high.
- The next scheduled reporting date is November 3, 2026, for third-quarter results.
Novo Nordisk stock is at EUR 34.88 at Lang & Schwarz on October 26, 2026 at 4:14 p.m. CEST, down 0.34 percent versus the Xetra close of October 23, 2026 at EUR 35.00. The key investor reference is an analyst target raised by Oddo BHF on October 20, 2026.
Oddo BHF lifts its target
According to MarketScreener, Oddo BHF raised its price target for Novo Nordisk from DKK 221 to DKK 305 and reiterated a Neutral rating. The target was lifted on October 20, 2026, while the Danish pharmaceutical company traded at a closing price of DKK 256.50 in the comparison cited by the report. The recommendation was unchanged, so the target increase does not amount to a new positive rating.
Stock stays below its yearly high
The euro quotation is 34.75 percent below the 52-week high of EUR 53.46 and 14.74 percent above the 52-week low of EUR 30.40. Both levels were reported for October 26, 2026, while the Xetra listing carried the ticker NOV and the home listing was Novo B on Nasdaq Copenhagen. Novo Nordisk's year-to-date performance was minus 20.02 percent in Danish kroner through October 23, 2026.
The stock's market value was DKK 1,150.6 billion on October 26, 2026. The latest market page also listed 66,700 employees and described diabetes and obesity treatments as 93.7 percent of net sales, with rare-disease treatments accounting for 6.3 percent.
Buyback meets the next results date
By October 16, 2026, Novo Nordisk had bought back 39.07 million B shares for DKK 10.88 billion, according to Boerse Express. The purchases had been made under the program since February 4, 2026, giving the capital return a defined time frame rather than linking it to one trading session.
The next scheduled reporting date is November 3, 2026, when Novo Nordisk is expected to release third-quarter results. MarketScreener lists the date as the next earnings release, making the upcoming report the next scheduled test for the business after the target revisions and buyback activity.
What the price position means
The immediate market picture combines a modest daily decline with a wide gap to the yearly high. The analyst target is denominated in Danish kroner, while the German quotation is in euros, so the two price levels are not combined into a single return calculation.
Novo Nordisk stock was trading at EUR 34.88 at Lang & Schwarz on October 26, 2026 at 4:14 p.m. CEST, 0.34 percent below the Xetra close of October 23, 2026 at EUR 35.00. The further course of trading is shown by the continuously updated real-time quote of Novo Nordisk stock.
Novo Nordisk stock facts
- Company: Novo Nordisk A/S
- ISIN: DK0062498333
- Ticker: NOVO B
- Primary exchange: Nasdaq Copenhagen
- Price Lang & Schwarz (as of October 26, 2026, 4:14 p.m. CEST): EUR 34.88
- Change versus Xetra close: minus 0.34 percent
- Xetra close (October 23, 2026): EUR 35.00
- Market capitalization: DKK 1,150.6 billion (as of October 26, 2026)
- 52-week range: EUR 30.40-EUR 53.46 (as of October 26, 2026)
- Sector / Industry: Pharmaceuticals
- Next earnings date: November 3, 2026
Market context: Latest market reports.
